Figure 6.

Dual treatment with K145 and bortezomib shows efficacy in an aggressive, bortezomib-resistant murine model of myeloma. A) Representative bioluminescence images showing disease burden in each treatment group of NSG mice after luciferin injection 14 days (pre-treatment), 21 days (after one week of treatment), and 28 days (after 2 weeks of treatment) post injection of two million 5TGM1.BR cells via the tail vein. B) Quantitation of myeloma disease burden (as average bioluminescent flux, measured in photons/sec ± SEM, of each treatment group after 28 days (two weeks of treatment)). # refer to panel D C) Mouse Kaplan-Meier survival curves for each treatment group from the day of treatment starting. Treatment was administered for 17 days (as indicated by the blue bar), and then the mice were monitored until their ethical end points were reached (p = 0.031, log-rank test). D) Average disease burden was compared to the combination group using a multivariable linear regression model adjusting for baseline disease burden, with the p-value shown alongside. A multi-variable Cox regression survival analysis adjusting for baseline disease burden was used to assess the risk of death between treatment groups. Hazard rations for each treatment group compared to the control group are shown, together with the p-values and 95% confidence intervals.